Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.

The Journal of antimicrobial chemotherapy - 1 May 2020

Elliot Emilie R, Neary Megan, Else Laura, Khoo Saye, Moyle Graeme, Carr Daniel F, Wang Xinzhu, Mcclure Myra, Boffito Marta, Owen Andrew

Abstract excerpt

OBJECTIVES: Dolutegravir has replaced efavirenz as first-line treatment in universal HIV guidelines. We sought to ascertain the contributory effect of SNPs in four key genes linked to dolutegravir disposition (UGT1A1, ABCG2, CYP3A and NR1I2) on plasma dolutegravir pharmacokinetics. METHODS: Paired pharmacogenetic/pharmacokinetic data from 93 subjects were analysed for association using multivariate linear...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Proteins

Share to Oxazines

Share to Piperazines

Share to Polymorphism, Single Nucleotide

Share to Pregnane X Receptor

Share to Pyridones

Source

Identifiers

PMID: 32011683
DOI: 10.1093/jac/dkz558

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.PMID 32011683Read ↗

Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.Semantic proximity Read ↗

Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review.Semantic proximity Read ↗

High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants.Semantic proximity Read ↗

Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency VirusSemantic proximity Read ↗

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

UGT1A1 regulatory variant with potential effect on efficacy of HIV and cancer drugs commonly prescribed in South Africa.Semantic proximity Read ↗

Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.Semantic proximity Read ↗

Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.Semantic proximity Read ↗

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.Semantic proximity Read ↗

The pharmacokinetics, pharmacodynamics and pharmacogenetics of Dolutegravir and Cobicistat in the treatment of HIVSemantic proximity Read ↗

Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.